Mayo Clinic to test vaccine designed to provide immune response against early breast lesions
JACKSONVILLE, Fla. ? Only about 35 percent of precancerous breast lesions morph into cancer if untreated, but physicians cannot identify which lesions are potentially dangerous. So all women diagnosed with ductal carcinoma in situ undergo traditional therapy of surgery and possibly hormonal therapy and radiation. Now, Mayo Clinic researchers are about to test a vaccine [...] (Source: Mayo Clinic Florida News)
Source: Mayo Clinic Florida News - January 31, 2017 Category: Hospital Management Source Type: news

New Research Shows Breast Cancer Precursor Treatment Causes Women to Live Longer
This study is particularly important because DCIS treatment includes radiotherapy, which can cause damage to nearby organs More and more people are becoming aware they have DCIS because it is something that shows up in breast cancer screenings—so more women are able to get treated if they have this form of cancer. For more information on the study, please visit “Women treated for precursor of breast cancer can expect to live as long as other women.” Follow NN/LM SCR on Twitter and like us on Facebook. (Source: Network News)
Source: Network News - January 31, 2017 Category: Databases & Libraries Authors: NN/LM South Central Region Tags: Consumer Health General (all entries) Patient Safety Public Health Research Source Type: news

Medical News Today: Women with noninvasive breast cancer live as long as other women
Women diagnosed with ductal carcinoma in situ have a slightly higher risk of dying from breast cancer, but a significantly lower all-mortality risk. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 30, 2017 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Women treated for early signs of breast cancer live LONGER
Women over the age of 50 with ductal carcinoma in situ - a precursor of breast cancer - were 10 per cent more likely to be alive ten years after their diagnosis than health women, Dutch researchers found. (Source: the Mail online | Health)
Source: the Mail online | Health - January 28, 2017 Category: Consumer Health News Source Type: news

Women treated for precursor of breast cancer can expect to live as long as other women
Women over 50 who have been treated for ductal carcinoma in situ (DCIS), a precursor of breast cancer, are more likely to be alive ten years later than women in the general population, according to new research. Researchers say these results should provide reassurance to women who are diagnosed with the disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 27, 2017 Category: Science Source Type: news

Good News for Older Women With Early Form of Breast Cancer
FRIDAY, Jan. 27, 2017 -- Older women treated for a very early form of breast cancer, called ductal carcinoma in situ (DCIS), do not have an overall increased risk of early death compared to their peers, a new study finds. " Being diagnosed with DCIS... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 27, 2017 Category: Journals (General) Source Type: news

Women treated for precursor of breast cancer can expect to live as long as other women
(ECCO-the European CanCer Organisation) Women over 50 who have been treated for ductal carcinoma in situ (DCIS), a precursor of breast cancer, are more likely to be alive ten years later than women in the general population, according to new research presented at the European Cancer Congress 2017. Researchers say these results should provide reassurance to women who are diagnosed with the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2017 Category: Cancer & Oncology Source Type: news

Study: Mammography Results in Overdiagnosis, No Reduction in Advanced Disease
Breast cancer screening was not associated with any reduction in the incidence of advanced cancer, and overdiagnosis of invasive tumors and ductal carcinoma in situ is a common problem, according to a new study conducted in Denmark. (Source: CancerNetwork)
Source: CancerNetwork - January 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Screening Source Type: news

Reoperation Rates 3-Fold Higher After DCIS Than IBC Reoperation Rates 3-Fold Higher After DCIS Than IBC
Patients undergoing breast-conserving surgery had reoperation rates 3 times higher when when their diagnosis was ductal carcinoma in situ (DCIS) than when it was invasive breast cancer (IBC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 9, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New ASTRO Guidelines for APBI in Early-Stage Breast Cancer New ASTRO Guidelines for APBI in Early-Stage Breast Cancer
The new guideline extends the candidates for accelerated partial-breast irradiation (APBI) to younger women and those with ductal carcinoma in situ.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Older DCIS Patients Have Low Rates of Tamoxifen, AI Usage
The initiation of and adherence to tamoxifen or aromatase inhibitors (AIs) such as anastrozole is low among older women with estrogen receptor-positive ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

Should DCIS Patients Get a Radiation Boost? Should DCIS Patients Get a Radiation Boost?
Pooled analysis of 4000 patients with ductal carcinoma in situ shows that a radiation boost reduces local recurrence.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Young Age and DCIS Tied to Increased Risk of Breast Tumor Recurrence Young Age and DCIS Tied to Increased Risk of Breast Tumor Recurrence
In women ages 40 and younger, the presence of ductal carcinoma in situ (DCIS) next to an invasive tumor is associated with an increased risk of ipsilateral breast tumor recurrence (IBTR), according to a recently published study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 16, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Current Trends in the Management of Ductal Carcinoma In Situ
This review will summarize the current trends in the diagnosis and management of DCIS and will highlight ongoing trials that are shaping future management of this entity. (Source: CancerNetwork)
Source: CancerNetwork - September 15, 2016 Category: Cancer & Oncology Authors: E. Shelley Hwang, MD, MPH Tristen S. Park, MD Tags: Breast Cancer Oncology Journal Review Article Source Type: news

Common breast cancer test may not be worth the cost, UCLA study suggests
A genomic test widely used to help determine whether women with a common form of breast cancer should undergo radiation is not cost effective, according to a new UCLA Jonsson Comprehensive Cancer Center study. The Oncotype DX DCIS test is given to women with ductal carcinoma in situ, which means the cancer has not spread to any other tissues, to help them choose the best treatment by better identifying the potential of tumors to come back.Oncotype DX DCIS reduces the number of women undergoing radiation therapy, which is good because it decreases the number of women exposed to possibly harmful side effects. However, UCLA J...
Source: UCLA Newsroom: Health Sciences - September 13, 2016 Category: Universities & Medical Training Source Type: news